Thomas Pisano - Nu Skin Independent Director
NUS Stock | USD 11.83 0.07 0.60% |
Director
Mr. Thomas R. Pisano is an Independent Director of Nu Skin Enterprises, Inc since 2008.
Age | 75 |
Tenure | 16 years |
Professional Marks | MBA |
Address | 75 West Center Street, Provo, UT, United States, 84601 |
Phone | 801 345 1000 |
Web | https://www.nuskin.com |
Nu Skin Management Efficiency
The company has Return on Asset of 0.0461 % which means that on every $100 spent on assets, it made $0.0461 of profit. This is way below average. Nu Skin's management efficiency ratios could be used to measure how well Nu Skin manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.01 in 2024. Return On Capital Employed is likely to drop to 0.04 in 2024. At this time, Nu Skin's Intangibles To Total Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 1.84 in 2024, whereas Total Assets are likely to drop slightly above 1.2 B in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Michel Dyens | Inter Parfums | 78 | |
Hunter Gary | Herbalife Nutrition | 44 | |
Veronique GabaiPinsky | Inter Parfums | 52 | |
Jerry McClain | USANA Health Sciences | 73 | |
Franklin Burke | Flowers Foods | 72 | |
Lawrence Kingsley | Polaris Industries | 58 | |
John Tartol | Herbalife Nutrition | 69 | |
Jean Levy | Inter Parfums | 83 | |
Nicholas Graziano | Herbalife Nutrition | 47 | |
Jesse Lynn | Herbalife Nutrition | 49 | |
Kevin Jones | Herbalife Nutrition | 52 | |
Melvin Stith | Flowers Foods | 74 | |
Kevin Farr | Polaris Industries | 63 | |
Richard Williams | USANA Health Sciences | 58 | |
Margaret Lewis | Flowers Foods | 66 | |
Martin Wood | Flowers Foods | 74 | |
Keith Cozza | Herbalife Nutrition | 37 | |
Joseph Shields | Flowers Foods | 79 | |
James Spear | Flowers Foods | 65 | |
Donald Williams | USANA Health Sciences | 59 | |
Peggie Pelosi | USANA Health Sciences | 65 |
Management Performance
Return On Equity | 0.01 | ||||
Return On Asset | 0.0461 |
Nu Skin Enterprises Leadership Team
Elected by the shareholders, the Nu Skin's board of directors comprises two types of representatives: Nu Skin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NUS. The board's role is to monitor Nu Skin's management team and ensure that shareholders' interests are well served. Nu Skin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nu Skin's outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott Pond, Director - Investor Relations | ||
Ritch Wood, CFO, Principal Accounting Officer and VP | ||
Zhequing Shen, Director | ||
Chayce Clark, Executive Vice President General Counsel | ||
Joseph Chang, Executive Vice President - Product Development, Chief Scientific Officer | ||
Emma Battle, Director | ||
Thomas Pisano, Independent Director | ||
Neil Offen, Independent Director | ||
Mark Adams, Chief Officer | ||
Zheqing Shen, Independent Director | ||
James Thomas, Chief Accounting Officer | ||
Mang Tang, Strategic Advisor | ||
Joe Sueper, Senior CTO | ||
Nevin Andersen, Independent Director | ||
Mark Lawrence, Chief Financial Officer, Executive Vice President | ||
Sandra Tillotson, Founder | ||
D Dorny, Executive Vice President, General Counsel, Secretary | ||
Daniel Campbell, Lead Independent Director | ||
Edwina Woodbury, Independent Director | ||
Truman Hunt, CEO and President and Director | ||
Laura Nathanson, Independent Director | ||
Steven Lund, Executive Chairman of the Board | ||
Matthew Dorny, VP, General Counsel and Secretary | ||
Connie Tang, Executive Vice President Chief Global Growth & customer Experience Officer | ||
Scott Schwerdt, President - Americas Region | ||
Blake Roney, Founder | ||
Andrew Lipman, Independent Director | ||
Ryan Napierski, President, Chief Executive Officer, Director |
NUS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nu Skin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.01 | ||||
Return On Asset | 0.0461 | ||||
Profit Margin | 0 % | ||||
Operating Margin | 0.19 % | ||||
Current Valuation | 912.71 M | ||||
Shares Outstanding | 49.66 M | ||||
Shares Owned By Insiders | 2.16 % | ||||
Shares Owned By Institutions | 85.19 % | ||||
Number Of Shares Shorted | 1.61 M | ||||
Price To Earning | 10.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nu Skin Enterprises. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for NUS Stock analysis
When running Nu Skin's price analysis, check to measure Nu Skin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Skin is operating at the current time. Most of Nu Skin's value examination focuses on studying past and present price action to predict the probability of Nu Skin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Skin's price. Additionally, you may evaluate how the addition of Nu Skin to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Nu Skin's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nu Skin. If investors know NUS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nu Skin listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.88) | Dividend Share 1.56 | Earnings Share 0.17 | Revenue Per Share 39.612 | Quarterly Revenue Growth (0.07) |
The market value of Nu Skin Enterprises is measured differently than its book value, which is the value of NUS that is recorded on the company's balance sheet. Investors also form their own opinion of Nu Skin's value that differs from its market value or its book value, called intrinsic value, which is Nu Skin's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nu Skin's market value can be influenced by many factors that don't directly affect Nu Skin's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nu Skin's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nu Skin is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nu Skin's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.